DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Courtney KD, Ma Y, de Leon AD. et al.
HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma.
Clin Cancer Res 2020;
26: 793-803
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.